Global Breast Cancer Diagnostics Market to Surpass USD 2 Billion by 2022
By HospiMedica International staff writers Posted on 16 Apr 2019 |
The global breast cancer diagnostics market is anticipated to register a modest CAGR of 4.7% between 2017 and 2022 to surpass USD 2 billion in revenues by the end of the forecast period.
The market growth is expected to be driven by a surge in the number of breast cancer cases, thereby increasing the need for efficient and initial detection, as well as by the introduction of high-end technological assistance to provide conclusive test results. These are the latest findings of Fact.MR, (Dublin, Ireland), a market research firm.
Based on test type, BRCA is expected to dominate the global breast cancer diagnostics market with the highest revenue share and achieve sales of USD 500 million by 2022-end. However, the CA test type segment is projected to register the highest CAGR in the breast cancer diagnostics market through 2022, followed by the ER and PR test type segments. HER 2 test is expected to be the second-largest test type segment in the global breast cancer diagnostics market, whereas revenues of the EGFR mutation test type segment are likely to remain low. Hospital-associated laboratories are expected to remain the largest end-user of breast cancer diagnostics globally and record the highest revenues by 2022-end, followed by independent diagnostic laboratories.
Geographically, North America has the highest revenue share in the global breast cancer diagnostics market and will retain its leading position with projected revenues of more than USD 800 million by 2022-end. On the other hand, Europe will have the second-largest share in revenues of the global breast cancer diagnostics market, while the regional markets in Japan and the Middle East & Africa (MEA) are projected to witness a slow growth during the forecast period.
Related Links:
Fact.MR
The market growth is expected to be driven by a surge in the number of breast cancer cases, thereby increasing the need for efficient and initial detection, as well as by the introduction of high-end technological assistance to provide conclusive test results. These are the latest findings of Fact.MR, (Dublin, Ireland), a market research firm.
Based on test type, BRCA is expected to dominate the global breast cancer diagnostics market with the highest revenue share and achieve sales of USD 500 million by 2022-end. However, the CA test type segment is projected to register the highest CAGR in the breast cancer diagnostics market through 2022, followed by the ER and PR test type segments. HER 2 test is expected to be the second-largest test type segment in the global breast cancer diagnostics market, whereas revenues of the EGFR mutation test type segment are likely to remain low. Hospital-associated laboratories are expected to remain the largest end-user of breast cancer diagnostics globally and record the highest revenues by 2022-end, followed by independent diagnostic laboratories.
Geographically, North America has the highest revenue share in the global breast cancer diagnostics market and will retain its leading position with projected revenues of more than USD 800 million by 2022-end. On the other hand, Europe will have the second-largest share in revenues of the global breast cancer diagnostics market, while the regional markets in Japan and the Middle East & Africa (MEA) are projected to witness a slow growth during the forecast period.
Related Links:
Fact.MR
Latest Business News
- Johnson & Johnson Acquires Cardiovascular Medical Device Company Shockwave Medical
- Mindray to Acquire Chinese Medical Device Company APT Medical
- Olympus Acquires Korean GI Stent Maker Taewoong Medical
- Karl Storz Acquires British AI Specialist Innersight Labs
- Stryker to Acquire French Joint Replacement Company SERF SAS
- Medical Illumination Acquires Surgical Lighting Specialist Isolux
- 5G Remote-Controlled Robots to Enable Even Cross-Border Surgeries
- International Hospital Federation Announces 2023 IHF Award Winners
- Unprecedented AI Integration Transforming Surgery Landscape, Say Experts
- New WHO Guidelines to Revolutionize AI in Healthcare
- Getinge Acquires US-Based Medical Equipment Provider Healthmark Industries
- Global Surgical Lights Market Driven by Increasing Number of Procedures
- Global Capsule Endoscopy Market Driven by Demand for Accurate Diagnosis of Gastrointestinal Conditions
- Global OR Integration Market Driven by Need for Improved Workflow Efficiency and Productivity
- Global Endoscopy Devices Market Driven by Increasing Adoption of Endoscopes in Surgical Procedures
- Global Minimally Invasive Medical Devices Market Driven by Benefits of MIS Procedures